Medicine
Vanflyta 26.5 mg tablet
Vanflyta 26.5 mg tablet is a prescription medicine containing Quizartinib for oral use, marketed by Daiichi Sankyo, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted from 15°C to 30°C…
Key facts
- Active ingredient (INN)
- Quizartinib
- Brand
- Vanflyta
- Strength
- 26.5 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 1 bottle
- Marketing authorisation holder
- Daiichi Sankyo
- Manufacturer
- Daiichi Sankyo
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted from 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01EX11 Quizartinib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 July 2023
- Identifiers
- RxCUI 2643054, 2643060, 2643062 +1DailyMed set ID 29cdbcfe-497d-4e78-bb7b-2d4acafe8e86NDC 65597-511Application NDA216993
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle in 1 carton / 14 tablet, film coated in 1 bottle | 65597-511-04 | Daiichi Sankyo | 20 July 2023 |
| 1 bottle in 1 carton / 28 tablet, film coated in 1 bottle | 65597-511-28 | Daiichi Sankyo | 20 July 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Quizartinib
Clinical summary
Quizartinib is a kinase inhibitor indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, among other approved uses. It is available as tablets for oral use. MedsAcross supplies Quizartinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about QuizartinibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- VANFLYTA prescribing information (Daiichi Sankyo) · U.S. National Library of Medicine, DailyMed
- Vanflyta: European public assessment report (EPAR) · European Medicines Agency
Need Vanflyta 26.5 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.